Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - GTCbio's (USA) June 2008

This article was originally published in Clinica

Executive Summary

GTCbio's 3rd Assay Development and Screening Technologies conference will be held from June 5-6 2008 in San Francisco, California. The meeting will provide delegates with critical information for usein the discovery and development of assays, while highlighting the latest screening technologies. Attendees will hear from leading researchers developing and using assays to advance their discovery pipelines. New developments in all areas of assay developments, including cell-based and, in vitro assays, high throughput screening, high content analysis, label-free technologies, and informatics, will be covered. To register, please contact GTCbio on tel: +1 626 256 6405; http://gtcbio.com/

You may also be interested in...



Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Topics

UsernamePublicRestriction

Register

MT046252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel